Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-027895
Filing Date
2022-08-04
Accepted
2022-08-04 06:04:25
Documents
58
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20220630.htm   iXBRL 10-Q 3020719
2 EX-31.1 agle-ex311_6.htm EX-31.1 16032
3 EX-31.2 agle-ex312_8.htm EX-31.2 16034
4 EX-32.1 agle-ex321_9.htm EX-32.1 7042
5 EX-32.2 agle-ex322_7.htm EX-32.2 7029
6 GRAPHIC gq44fyizxb4r000001.jpg GRAPHIC 191074
  Complete submission text file 0001564590-22-027895.txt   9106395

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA agle-20220630.xsd EX-101.SCH 42686
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20220630_cal.xml EX-101.CAL 45703
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20220630_def.xml EX-101.DEF 136666
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20220630_lab.xml EX-101.LAB 342514
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20220630_pre.xml EX-101.PRE 252609
52 EXTRACTED XBRL INSTANCE DOCUMENT agle-10q_20220630_htm.xml XML 1664745
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 221134453
SIC: 2834 Pharmaceutical Preparations